...
首页> 外文期刊>Organic process research & development >A Single-Pot Synthesis of Atovaquone: An Antiparasitic Drug of Choice
【24h】

A Single-Pot Synthesis of Atovaquone: An Antiparasitic Drug of Choice

机译:单药合成的Atovaquone:首选的抗寄生虫药物

获取原文
获取原文并翻译 | 示例

摘要

The present article relates to a practical, economically viable, and validated at industrial scale, single-pot synthetic route for preparation of atovaquone, one of the most versatile antiparasitic drugs of choice used for the prophylaxis and treatment of diseases such as Pneumocystis, toxoplasmosis, babesiosis, coccidiosis, and malaria. However, owing to the extremely poor yields of syndiesis and very high doses of treatment (due to poor bioavailability) the cost of treatment with this drug is not affordable by the patients in need, particularly in the third world countries where these diseases are most prevalent. Unlike most of the reported processes which use 2-chloronaphthoquinone and pure rrans-4-chlorophenyl cyclohexane carboxylic acid, our process is based on the decarboxylative alkylation of isomeric mixture of 4-chlorophenyl cyclohexane carboxylic acid with 1,4-naphthoquinone to give 42% overall yield of atovaquone, 10 times higher than from the reported process (4%) from the innovators of this drug.
机译:本文涉及一种实用,经济可行且在工业规模上得到验证的单罐合成路线,用于制备阿托伐醌,它是预防和治疗疾病如肺孢子虫,弓形虫病的最通用的抗寄生虫药物之一巴贝病,球虫病和疟疾。但是,由于突触收率极低且治疗剂量很高(由于生物利用度差),有需要的患者无法负担得起这种药物的治疗费用,尤其是在这些疾病最普遍的第三世界国家。与大多数报告的使用2-氯萘醌和纯Rrans-4-氯苯基环己烷羧酸的方法不同,我们的方法基于4-氯苯基环己烷羧酸与1,4-萘醌的异构体混合物的脱羧烷基化,从而得到42%阿托伐醌的总收率是该药物创新者报道的方法(4%)的10倍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号